Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: Binding antibodies predict neutralizing antibody development

Multiple Sclerosis Journal

Volumn 20, Issue 5, 2014, Pages 577-587

  Hegen, H ^a   Millonig, A ^a   Bertolotto, A ^b   Comabella, M ^c   Giovanonni, G ^d   Guger, M ^e   Hoelzl, M ^a   Khalil, M ^f   Killestein, J ^g   Lindberg, R ^h   Malucchi, S ^b   Mehling, M ^h   Montalban, X ^c   Polman, C H ^g   Rudzki, D ^a   Schautzer, F ⁱ   Sellebjerg, F ^j   Sorensen P S ^j   Deisenhammer, F ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e KEPLER UNIVERSITY HOSPITAL   (Austria)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ Clinical Department of Neurology   (Austria)

^j Rigshospitalet   (Denmark)

more..

Author keywords

Binding antibody; biomarker; clinically isolated syndrome; CXCL 10; drug resistance; interferon beta; multicenter study; multiple sclerosis; myxovirus protein A; neutralizing antibody; sTRAIL

Indexed keywords

BETA1A INTERFERON; BIOLOGICAL MARKER; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; INTERFERON BETA SERINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYXOVIRUS PROTEIN A; NEUTRALIZING ANTIBODY; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VIRUS PROTEIN; BETA INTERFERON; CXCL10 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; MX1 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN; TNFSF10 PROTEIN, HUMAN; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOTHERAPY; INTRAMUSCULAR IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SUBCUTANEOUS IMMUNOTHERAPY; BLOOD; CLINICAL TRIAL; DEMYELINATING DISEASES; EARLY DIAGNOSIS; EUROPE; GENETICS; IMMUNOLOGY; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TIME; TREATMENT OUTCOME; DEMYELINATING DISEASE; DRUG RESPONSE; OUTCOME ASSESSMENT; PREDICTION; PROTEIN EXPRESSION; RELIABILITY;

ADULT; ANTIBODIES, NEUTRALIZING; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; DEMYELINATING DISEASES; EARLY DIAGNOSIS; EUROPE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYXOVIRUS RESISTANCE PROTEINS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TREATMENT OUTCOME;

EID: 84899114713     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513503597     Document Type: Article

References (35)

1. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: Prevalence and impact on outcomes. CNS Drugs. 2009 ; 23: 379-396
2. Perini P, Calabrese M, Biasi G, et al. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol. 2004 ; 251: 305-309
3. Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology. 2005 ; 65: 33-39
4. Gneiss C, Tripp P, Reichartseder F, et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler. 2006 ; 12: 731-737
5. Mayr M, Berek K, Deisenhammer F. Evolution of interferon-beta binding antibodies in MS patients may predict development of neutralizing antibodies. Eur J Neurol. 2003 ; 10: 462-464
6. Deisenhammer F, Reindl M, Harvey J, et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology. 1999 ; 52: 1239-1243
7. Von Wussow P, Jakschies D, Hochkeppel HK, et al. The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol. 1990 ; 20: 2015-2019
8. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010 ; 9: 740-750
9. Lünemann JD, Waiczies S, Ehrlich S, et al. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol. 2002 ; 168: 4881-4888
10. Buttmann M, Merzyn C, Hofstetter HH, et al. TRAIL, CXCL10 and CCL2 plasma levels during long-term interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. J Neuroimmunol. 2007 ; 190: 170-176
11. Kurne A, Guc D, Canpinar H, et al. Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: Evaluation of expression under immunomodulatory therapy. Acta Neurol Scand. 2011 ; 123: 8-12
12. Buttmann M, Merzyn C, Rieckmann P. Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J Neuroimmunol. 2004 ; 156: 195-203
13. Sellebjerg F, Krakauer M, Hesse D, et al. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur J Neurol. 2009 ; 16: 1291-1298
14. Comabella M, Río J, Espejo C, et al. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin Immunol. 2009 ; 130: 145-150
15. Alexander JS, Harris MK, Wells SR, et al. Alterations in serum MMP-8, MMP-9, IL-12 p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler. 2010 ; 16: 801-809
16. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 Revisions to the "McDonald Criteria.". Ann Neurol. 2005 ; 58: 840-846
17. Farrell R, Kapoor R, Leary S, et al. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of interferon-beta. Mult Scler. 2008 ; 14: 212-218
18. Lam R, Farrell R, Aziz T, et al. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Meth. 2008 ; 336: 113-118
19. Gneiss C, Brugger M, Millonig A, et al. Comparative study of four different assays for the detection of binding antibodies against interferon-beta. Mult Scler. 2008 ; 14: 830-836
20. Millonig A, Rudzki D, Holzl M, et al. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): A pilot study. Mult Scler. 2009 ; 15: 977-983
21. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002 ; 1: 457-462
22. Kivisäkk P, Alm G, Fredrikson S, et al. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol. 2000 ; 7: 27-34
23. Kivisäkk P, Alm GV, Tian WZ, et al. Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis. Mult Scler. 1997 ; 3: 184-190
24. Pachner A, Cadavid D, Wolansky L, et al. Effect of anti-IFNbeta antibodies on MRI lesions of MS patients in the BECOME study. Neurology. 2009 ; 73: 1485-1492
25. Sominanda A, Hillert J, Fogdell-Hahn A. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry. 2008 ; 79: 57-62
26. Bertolotto A, Malucchi S, Milano E, et al. Interferon beta neutralizing antibodies in multiple sclerosis: Neutralizing activity and cross-reactivity with three different preparations. Immunopharmacol. 2000 ; 48: 95-100
27. Cepok S, Schreiber H, Hoffmann S, et al. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol. 2009 ; 66: 1216-1223
28. Gilli F, Marnetto F, Caldano M, et al. Biological markers of interferon beta therapy: Comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler. 2006 ; 12: 47-57
29. Hong J, Zang YC, Hutton G, et al. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004 ; 152: 126-139
30. Pachner AR, Dail D, Pak E, et al. The importance of measuring IFN beta bioactivity: Monitoring in MS patients and the effect of anti-IFN beta antibodies. J Neuroimmunol. 2005 ; 166: 180-188
31. Gneiss C, Tripp P, Ehling R, et al. Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies. J Neuroimmunol. 2006 ; 174: 174-179
32. Gibbs E, Oger J. A biosensor-based characterization of the affinity maturation of the immune response against interferon-beta and correlations with neutralizing antibodies in treated multiple sclerosis patients. J Interferon Cytokine Res. 2008 ; 28: 713-723
33. Hegen H, Schleiser M, Gneiss C, et al. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Mult Scler. 2012 ; 18: 610-615
34. Gilli F, Hoffmann F, Sala A, et al. Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis. Mult Scler. 2006 ; 12: 738-746
35. Bendtzen K. Anti-IFN BAb and NAb antibodies: A minireview. Neurology. 2003 ; 61: S6-10